From: Association of systemic lupus erythematosus autoantibody diversity with breast cancer protection
Site | No. obs. | No. exp. | SLE cohort SIR (95%CI) | p value | AA* SIR (95%CI) | AA p value | Non-AA^ SIR (95%CI) | Non-AA p value |
---|---|---|---|---|---|---|---|---|
All | 119 | 102.3 | 1.16 (0.96–1.39) | 0.12 | 1.63 (1.26–2.08) | < 0.001 | 0.86 (0.65–1.13) | 0.31 |
Female cancers | ||||||||
Breast | 22 | 34.9 | 0.63 (0.39–0.95) | 0.027 | 1.13 (0.65–1.84) | 0.69 | 0.29 (0.11–0.63) | < 0.001 |
Cervix | 11 | 4 | 2.73 (1.36–4.89) | 0.006 | 3.78 (1.52–7.79) | 0.006 | 1.84 (0.50–4.71) | 0.35 |
Vagina/vulva | 13 | 1.9 | 6.87 (3.66–11.8) | < 0.001 | 14.13 (7.05–25.3) | < 0.001 | 1.80 (0.22–6.49) | 0.61 |
Other cancers | ||||||||
Hematologic | 10 | 6.5 | 1.54 (0.74–2.84) | 0.24 | 1.87 (0.61–4.36) | 0.27 | 1.31 (0.43–3.07) | 0.67 |
Lung | 11 | 8.7 | 1.27 (0.63–2.26) | 0.52 | 1.84 (0.74–3.80) | 0.18 | 0.82 (0.22–2.09) | 0.92 |
Colorectal | 10 | 7.2 | 1.39 (0.66–2.55) | 0.38 | 1.18 (0.32–3.01) | 0.88 | 1.57 (0.58–3.42) | 0.37 |
Thyroid | 9 | 4 | 2.27 (1.04–4.30) | 0.041 | 0.00 (0–3.31) | 0.66 | 3.15 (1.44–5.98) | 0.006 |
Melanoma | 8 | 5.4 | 1.48 (0.64–2.91) | 0.36 | 0.00 (0–37.3) | 0.99 | 1.51 (0.65–2.97) | 0.34 |
HPV-associated cancers** | 26 | 5.9 | 4.39 (2.87–6.44) | < 0.001 | 7.23 (4.35–11.3) | < 0.001 | 2.13 (0.86–4.38) | 0.10 |